Published in J Med Chem on January 08, 1993
Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity. Antimicrob Agents Chemother (2002) 2.21
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent. Antimicrob Agents Chemother (2002) 1.28
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother (1999) 1.26
Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys. Antimicrob Agents Chemother (1996) 0.96
Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro. Antimicrob Agents Chemother (2003) 0.83
Enzymatic assay for measurement of intracellular DXG triphosphate concentrations in peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother (2003) 0.82
Synthesis and anti-HIV activity of (-)-beta-D-(2R,4R)-1,3-dioxolane-2,6-diamino purine (DAPD) (amdoxovir) and (-)-beta-D-(2R,4R)-1,3-dioxolane guanosine (DXG) prodrugs. Antiviral Res (2007) 0.81
Adenosine Dioxolane Nucleoside Phosphoramidates as Antiviral Agents for Human Immunodeficiency and Hepatitis B Viruses. ACS Med Chem Lett (2013) 0.77
Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother (2007) 0.76
Scaleable processes for the synthesis of (-)-β-D-2,6-diaminopurine dioxolane (Amdoxovir, DAPD) and (-)-β-D-2-aminopurine dioxolane (APD). Tetrahedron (2012) 0.75
Anti-human immunodeficiency virus activities of nucleosides and nucleotides: correlation with molecular electrostatic potential data. Antimicrob Agents Chemother (2000) 0.75
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol (2000) 5.76
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother (1993) 5.08
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A (1991) 3.82
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother (1997) 2.64
Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1990) 2.53
Abdominal injuries without hemoperitoneum: a potential limitation of focused abdominal sonography for trauma (FAST) J Trauma (1997) 2.36
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
Using CT to diagnose traumatic lumbar hernia. AJR Am J Roentgenol (2000) 2.29
Helical CT of diaphragmatic rupture caused by blunt trauma. AJR Am J Roentgenol (1999) 2.24
Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother (1992) 2.17
Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2',3'-dideoxy-3'-thiacytidine in the inhibition of hepatitis B virus replication. J Biol Chem (1992) 2.13
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis (1999) 2.07
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Using CT to diagnose tracheal rupture. AJR Am J Roentgenol (2001) 1.90
Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol (1987) 1.89
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
Helical computed tomography of bowel and mesenteric injuries. J Trauma (2001) 1.63
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol (1993) 1.56
Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother (2000) 1.49
Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother (1982) 1.48
Complications of ultrasound-guided transperineal prostate biopsy. A prospective study. Br J Urol (1993) 1.48
Antileukemic effects of pseudoisocytidine, a new synthetic pyrimidine C-nucleoside. Cancer Res (1976) 1.44
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother (1994) 1.43
Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother (1996) 1.42
The Problem of Finance in Rural Health Practice. Am J Public Health Nations Health (1929) 1.42
Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest (1995) 1.42
Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother (1981) 1.41
Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother (1988) 1.40
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother (1995) 1.39
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis (2001) 1.38
Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother (1995) 1.38
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother (1988) 1.36
Mechanically adaptive intracortical implants improve the proximity of neuronal cell bodies. J Neural Eng (2011) 1.33
Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). J Med Chem (1988) 1.33
Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol (2000) 1.30
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother (1986) 1.28
Multiple drug effect analysis with confidence interval. Antiviral Res (1994) 1.26
3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses (1990) 1.24
Imaging of traumatic diaphragmatic injuries. Semin Ultrasound CT MR (2002) 1.23
All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat (2013) 1.23
Pure nucleoside enantiomers of beta-2',3'-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother (1994) 1.23
CT findings after embolization for blunt splenic trauma. J Vasc Interv Radiol (2001) 1.22
Blunt abdominal trauma patients: can organ injury be excluded without performing computed tomography? J Trauma (2004) 1.21
Effect of beta-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells. Implications for predicting drug hepatotoxicity. Biochem Pharmacol (1996) 1.20
Lobeline and structurally simplified analogs exhibit differential agonist activity and sensitivity to antagonist blockade when compared to nicotine. Neuropharmacology (1998) 1.17
Mechanism of action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-beta-D-dioxolane guanosine. Antimicrob Agents Chemother (2001) 1.17
Gallbladder injury secondary to blunt trauma: CT findings. J Comput Assist Tomogr (1994) 1.15
Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother (1989) 1.15
Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2',3'-dideoxy-3'-thiacytidine in normal human bone marrow progenitor cells. Biochem Pharmacol (1992) 1.15
Synthesis and biological activities of 5-(hydroxymethyl, azidomethyl, or aminomethyl)-2'-deoxyuridine and related 5'-substituted analogues. J Med Chem (1980) 1.14
Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells. Biochem Pharmacol (1988) 1.14
Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol (1991) 1.14
Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother (2001) 1.12
Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother (1994) 1.12
Multidetector-row CT of right hemidiaphragmatic rupture caused by blunt trauma: a review of 12 cases. Clin Radiol (2005) 1.11
Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat (2008) 1.11
Marine natural products as lead anti-HIV agents. Mini Rev Med Chem (2003) 1.11
Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus. Antimicrob Agents Chemother (1983) 1.11
Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res (1990) 1.10
Pharmacokinetics of a water-soluble fullerene in rats. Antimicrob Agents Chemother (1996) 1.10
Synthesis and cytotoxic activity of N-substituted thiosemicarbazones of 3-(3,4-methylenedioxy)phenylpropanal. Farmaco (1998) 1.09
A chemiluminescence immunoassay for evaluation of Cryptosporidium parvum growth in vitro. FEMS Microbiol Lett (1996) 1.09
YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine. J Viral Hepat (2003) 1.08
Acute adrenal injury after blunt abdominal trauma: CT findings. AJR Am J Roentgenol (1992) 1.08
Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrob Agents Chemother (1994) 1.08
L- and D-enantiomers of 2',3'-dideoxycytidine 5'-triphosphate analogs as substrates for human DNA polymerases. Implications for the mechanism of toxicity. J Biol Chem (1995) 1.07
Human immunodeficiency virus in semen and plasma: investigation of sexual transmission risk behavioral correlates. AIDS Res Hum Retroviruses (2001) 1.06
Chance-type fractures of the thoracolumbar spine: imaging analysis in 53 patients. AJR Am J Roentgenol (2006) 1.05
Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro. Biochem Pharmacol (1987) 1.05
Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir Ther (1999) 1.04
L-beta-(2S,4S)- and L-alpha-(2S,4R)-dioxolanyl nucleosides as potential anti-HIV agents: asymmetric synthesis and structure-activity relationships. J Med Chem (1993) 1.04
CT criteria for management of blunt liver trauma: correlation with angiographic and surgical findings. Radiology (2000) 1.03
Pharmacokinetics of (-)-beta-D-dioxolane guanine and prodrug (-)-beta-D-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res Hum Retroviruses (1999) 1.03
Polyoxometalate HIV-1 protease inhibitors. A new mode of protease inhibition. J Am Chem Soc (2001) 1.03
Multidetector CT evaluation of abdominal trauma. Radiol Clin North Am (2005) 1.03
Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells. Biochem Pharmacol (1997) 1.01